Related Experiment Video
Updated: May 12, 2026
Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
Published on: May 19, 2018
Can hepatoma cell lines be redifferentiated to be used in drug metabolism studies?
Celia P Martínez-Jiménez1, Ramiro Jover, Maria José Gómez-Lechón
1Unit of Experimental Hepatology, University Hospital "La Fe" Valencia, Spain.
Abstract:
Knowledge of metabolism, enzymes so far involved, and potential enzyme-inhibiting or enzyme-inducing properties of new compounds is a key issue in drug development. Primary cultured hepatocytes, cytochrome P450 (CYP)-engineered cells and hepatoma cell lines are currently being used for this purpose, but only primary cultures can produce a metabolic profile of a drug similar to that found in vivo and can respond to inducers. Because of their limited accessibility, alternatives to replace human hepatocytes are currently being explored, including the immortalisation of hepatocytes by using different strategies (i.e. SV40 T-large antigen, conditionally immortalised hepatocytes, transfection with c-myc, cH-ras, N-ras oncogenes, transgenic animals over-expressing growth factors or oncogenes and cre-lox recombination/excision). However, none of the resulting cells has the desirable phenotypic characteristics to replace primary cultures in drug metabolisms studies. We investigated why these differentiated human hepatomas do not express CYP genes and found that the levels of certain key transcription factors clearly differ from those found in hepatocytes. It was then conceivable that re-expression of one (or more) of these transcription factors could lead to an efficient transcription of CYP genes. The feasibility of this hypothesis was demonstrated by genetic engineering of Hep G2 cells with liver-enriched transcription factors followed by the analysis of the expression of the most relevant human CYPs.
Insights
Researchers genetically engineered Hep G2 cells with liver-enriched transcription factors to restore cytochrome P450 (CYP) gene expression, offering a potential in vitro model for drug metabolism studies.
Area of Science:
- Drug metabolism and development
- Hepatocyte cell biology
- Genetic engineering and molecular biology
Background:
- Understanding drug metabolism, including enzyme activity and compound interactions, is crucial for drug development.
- Primary human hepatocytes provide the most accurate in vitro model for drug metabolism but are limited in accessibility.
- Current immortalized cell lines and engineered cells lack the full metabolic profile and responsiveness of primary hepatocytes.
Purpose of the Study:
- To investigate the reasons behind the lack of cytochrome P450 (CYP) gene expression in human hepatoma cell lines.
- To determine if re-expressing key transcription factors could restore CYP gene transcription in these cells.
- To develop a more suitable in vitro model for drug metabolism studies by enhancing hepatoma cell functionality.
Main Methods:
- Analysis of key transcription factor levels in differentiated human hepatoma cells compared to primary hepatocytes.
- Genetic engineering of Hep G2 cells to introduce and express specific liver-enriched transcription factors.
- Quantitative analysis of relevant human CYP gene expression in engineered Hep G2 cells.
Main Results:
- Significant differences in key transcription factor levels were identified between hepatoma cells and primary hepatocytes.
- Genetic engineering successfully led to the re-expression of liver-enriched transcription factors in Hep G2 cells.
- The re-expression of these factors resulted in the efficient transcription of major human CYP genes.
Conclusions:
- Key transcription factors play a critical role in regulating CYP gene expression in hepatocytes.
- Genetic modification of hepatoma cells with these factors can restore CYP gene expression, creating a potentially valuable in vitro model.
- This approach offers a promising alternative to primary hepatocytes for drug metabolism and enzyme induction studies.
